Galinpepimut-S therapy showed specific T-Cell immune responses for patients with acute myeloid leukemia in remission ...

Myeloid lineage cells, including macrophages, dendritic cells, osteoclasts and precursor cells, all produce VEGF-C in response to inflammatory cytokines, which is mediated by the canonical NF-κB ...

The TREM2 receptor may hold the keys to understanding how myeloid cells affect immune responses to neurological disorders and cancer. Triggering receptors expressed on myeloid cells (TREMs) are a cell ...

A research team made a pivotal discovery in the field of cancer immunotherapy. The team identified a specific population of immune cells that play a critical role in successful treatment of relapsed ...

A research team from Columbia Engineering and the Irving Institute for Cancer Dynamics achieved a significant finding in ...

In a paper published in Science Bulletin, a Chinese team of scientists reported a comprehensive proteogenomic analysis of 101 Chinese AML patients, including proteomic and phosphoproteomic analyses ...

The following is a summary of “Protocol of a decisional intervention for older adults with newly diagnosed acute myeloid ...

Ltd. have published findings from their work aiming to identify antigens that could represent novel targets for CAR T-cell therapies against acute myeloid leukemia (AML).

KAT2A is a histone acetyltransferase that functions as a transcriptional activator which, together with its paralogue KAT2B, is markedly overexpressed in acute myeloid leukemia (AML) compared to in ...